NCT03214003

Twice-daily SIB Radiotherapy Versus Standard Radiotherapy for Patients With SCLC

Twice-daily Radiotherapy by Simultaneous Integrated Boosting Technique Versus Twice-daily Standard Radiotherapy for Patients With Limited-stage Small Cell Lung Cancer: a Multicenter, Randomized, Controlled, Phase III Study

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 235 (actual)
• Sponsor: Anhui Shi, MD · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This trial is a multicenter, perspective, non-blinded, randomized controlled phase 3 trial. In order to establish whether the SIB technique can improve the results of twice-daily chemo-RT for patients with LS-SCLC, the investigators will primarily compare survival of patients treated with standard chemotherapy (cisplatin and etoposide) and either SIB twice-daily RT or standard dose twice-daily RT.

Detailed description

Three hundred and twenty-six patients with a histological or cytological proven diagnosis of SCLC will be recruited from 35 centers in 14 areas including provinces, municipalities and autonomous region, from May 2017 to May 2020.

Conditions

• Small Cell Lung Cancer Limited Stage
• Radiotherapy

Interventions

Type	Name	Description
RADIATION	SIB	patients will recieve twice-daily radiotherapy by simultaneous integrated boosting technique concurrent with chemotherapy
RADIATION	Standard	patients will recieve standard twice-daily radiotherapy concurrent with chemotherapy

Timeline

• Start date: 2017-06-30
• Primary completion: 2021-04-30
• Completion: 2023-01-30
• First posted: 2017-07-11
• Last updated: 2023-06-22

Locations

1 site across 1 country: China